Faull C M, Rooke P, Baylis P H
Department of Medicine, Medical School, University of Newcastle upon Tyne, UK.
Clin Endocrinol (Oxf). 1991 Nov;35(5):423-30. doi: 10.1111/j.1365-2265.1991.tb03560.x.
To explore a possible interaction of the serotonin neurotransmitter system and posterior pituitary function, we have looked at the effect of fluoxetine treatment on osmoregulated vasopressin secretion in normal men in two placebo controlled studies.
In each study subjects took in random order for 7 days one capsule daily of placebo or 40 mg fluoxetine. On the 8th day subjects underwent assessment. Study 1 A hypo-osmotic stimulus of an oral water load of 20 ml/kg. Study 2 A hyperosmotic stimulus of intravenous infusion of 5% (855 mmol/l) saline at 0.06 ml/kg/min for 120 minutes.
Normal, healthy male volunteers. Study 1, 9; Study 2, 10.
In both studies regular measures of plasma osmolality, sodium and vasopressin were made. In Study 1 urine osmolality was measured together with urine volume at set time points and an accumulative measure of percentage of water load excreted. Free water clearance was calculated. In Study 2 the relationship of plasma vasopressin to change in plasma osmolality was calculated for each subject by linear regression analysis.
Serotonin agonism had no effect on baseline measurements in either study. Study 1 After 4 hours subjects excreted 95 and 99% of the water load after placebo and fluoxetine respectively (P = 0.407). There was no effect of fluoxetine compared to placebo on the pattern or extent of change of plasma osmolality (nadir 285.9 +/- 1.4 mosm/kg placebo, 283.1 +/- 1.1 mosm/kg fluoxetine, P = 0.145) or free water clearance or maximum urine dilution after oral water loading. Plasma vasopressin suppressed to a minimum concentration after both treatments in response to hypo-osmolality 0.5 +/- 0.1 pmol/l (placebo), 0.3 +/- 0.01 pmol/l (fluoxetine), P = 0.195. Study 2 Fluoxetine had no significant effect on the sensitivity of vasopressin release to change in plasma osmolality (0.33 +/- 0.06 pmol/l per mosm/kg placebo, 0.36 +/- 0.06 pmol/l per mosm/kg fluoxetine, P = 0.347). Nor was there a significant effect on the theoretical osmotic threshold for release of vasopressin (287.0 +/- 1.21 mosm/kg placebo, 286.9 +/- 1.09 mosm/kg fluoxetine, P = 0.700).
We have found no evidence of a physiologically relevant effect of serotonin agonism on osmoregulated vasopressin release, or on the ability of normal man to excrete a water load. The possible reasons for this contrast to animal work are discussed.
为探究血清素神经递质系统与垂体后叶功能之间可能存在的相互作用,我们在两项安慰剂对照研究中观察了氟西汀治疗对正常男性渗透压调节性血管加压素分泌的影响。
在每项研究中,受试者随机顺序连续7天每日服用1粒安慰剂胶囊或40毫克氟西汀。在第8天对受试者进行评估。研究1:口服20毫升/千克的低渗性水负荷刺激。研究2:以0.06毫升/千克/分钟的速度静脉输注5%(855毫摩尔/升)盐水120分钟进行高渗性刺激。
正常、健康的男性志愿者。研究1有9名;研究2有10名。
在两项研究中均定期测量血浆渗透压、钠和血管加压素。在研究1中,在设定时间点测量尿渗透压、尿量以及排出水负荷百分比的累积量。计算自由水清除率。在研究2中,通过线性回归分析计算每个受试者血浆血管加压素与血浆渗透压变化之间的关系。
血清素激动剂对两项研究中的基线测量均无影响。研究1:4小时后,服用安慰剂和氟西汀的受试者分别排出了95%和99%的水负荷(P = 0.407)。与安慰剂相比,氟西汀对血浆渗透压变化的模式或程度(最低点:安慰剂组为285.9±1.4毫渗量/千克,氟西汀组为283.1±1.1毫渗量/千克,P = 0.145)、自由水清除率或口服水负荷后的最大尿液稀释度均无影响。在低渗状态下,两种治疗后血浆血管加压素均抑制至最低浓度,分别为0.5±0.1皮摩尔/升(安慰剂)、0.3±(此处似乎少了个数字)0.01皮摩尔/升(氟西汀),P = 0.195。研究2:氟西汀对血管加压素释放对血浆渗透压变化的敏感性无显著影响(安慰剂组为每毫渗量/千克0.33±0.06皮摩尔/升,氟西汀组为每毫渗量/千克0.36±0.06皮摩尔/升,P = 0.347)。对血管加压素释放的理论渗透阈值也无显著影响(安慰剂组为287.0±1.21毫渗量/千克,氟西汀组为286.9±1.09毫渗量/千克,P = 0.700)。
我们未发现血清素激动剂对渗透压调节性血管加压素释放或正常男性排出水负荷能力有生理相关影响的证据。讨论了与动物研究结果存在差异的可能原因。